DiscoverCME in Minutes: Education in DermatologyTina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape
Tina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape

Tina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape

Update: 2025-12-09
Share

Description

Please visit answersincme.com/860/99534447-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Tina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape

Tina Bhutani, MD, MAS, FAAD / Robin K. Dore, MD - The Dermatology-Rheumatology Psoriatic Playbook: Advancing Care With Novel Oral Therapies in the Evolving PsA Landscape

Answers in CME